The adjustment in price target by a prominent analyst like Anupam Rama, while maintaining an Overweight rating, suggests a continued positive outlook on Sage Therapeutics with a slight adjustment in valuation expectations. This could lead to mixed reactions in the short term, as the market digests the slight decrease in target price against the backdrop of an overall positive rating.